Biotech | August 10, 2021
Eagle Pharmaceuticals announces licensing agreement for Landiolol
Deal signed with AOP Orphan for US commercial rights
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
The transaction is expected to close in the Q4FY22
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
It is part of the company’s pain/analgesics portfolio of OTC products
Subscribe To Our Newsletter & Stay Updated
